Literature DB >> 26917724

Nerve Injury Diminishes Opioid Analgesia through Lysine Methyltransferase-mediated Transcriptional Repression of μ-Opioid Receptors in Primary Sensory Neurons.

Yuhao Zhang1, Shao-Rui Chen1, Geoffroy Laumet1, Hong Chen1, Hui-Lin Pan2.   

Abstract

The μ-opioid receptor (MOR, encoded by Oprm1) agonists are the mainstay analgesics for treating moderate to severe pain. Nerve injury causes down-regulation of MORs in the dorsal root ganglion (DRG) and diminishes the opioid effect on neuropathic pain. However, the epigenetic mechanisms underlying the diminished MOR expression caused by nerve injury are not clear. G9a (encoded by Ehmt2), a histone 3 at lysine 9 methyltransferase, is a key chromatin regulator responsible for gene silencing. In this study, we determined the role of G9a in diminished MOR expression and opioid analgesic effects in animal models of neuropathic pain. We found that nerve injury in rats induced a long-lasting reduction in the expression level of MORs in the DRG but not in the spinal cord. Nerve injury consistently increased the enrichment of the G9a product histone 3 at lysine 9 dimethylation in the promoter of Oprm1 in the DRG. G9a inhibition or siRNA knockdown fully reversed MOR expression in the injured DRG and potentiated the morphine effect on pain hypersensitivity induced by nerve injury. In mice lacking Ehmt2 in DRG neurons, nerve injury failed to reduce the expression level of MORs and the morphine effect. In addition, G9a inhibition or Ehmt2 knockout in DRG neurons normalized nerve injury-induced reduction in the inhibitory effect of the opioid on synaptic glutamate release from primary afferent nerves. Our findings indicate that G9a contributes critically to transcriptional repression of MORs in primary sensory neurons in neuropathic pain. G9a inhibitors may be used to enhance the opioid analgesic effect in the treatment of chronic neuropathic pain.
© 2016 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  electrophysiology; epigenetics; neuron; neurophysiology; opiate opioid; pain

Mesh:

Substances:

Year:  2016        PMID: 26917724      PMCID: PMC4861421          DOI: 10.1074/jbc.M115.711812

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  49 in total

1.  Role of histone H3 lysine 9 methylation in epigenetic control of heterochromatin assembly.

Authors:  J Nakayama ; J C Rice; B D Strahl; C D Allis; S I Grewal
Journal:  Science       Date:  2001-03-15       Impact factor: 47.728

2.  Actions of opioids on excitatory and inhibitory transmission in substantia gelatinosa of adult rat spinal cord.

Authors:  T Kohno; E Kumamoto; H Higashi; K Shimoji; M Yoshimura
Journal:  J Physiol       Date:  1999-08-01       Impact factor: 5.182

3.  Direct interaction between DNMT1 and G9a coordinates DNA and histone methylation during replication.

Authors:  Pierre-Olivier Estève; Hang Gyeong Chin; Andrea Smallwood; George R Feehery; Omkaram Gangisetty; Adam R Karpf; Michael F Carey; Sriharsa Pradhan
Journal:  Genes Dev       Date:  2006-11-03       Impact factor: 11.361

Review 4.  Chromatin modifications and their function.

Authors:  Tony Kouzarides
Journal:  Cell       Date:  2007-02-23       Impact factor: 41.582

5.  Opiate receptor knockout mice define mu receptor roles in endogenous nociceptive responses and morphine-induced analgesia.

Authors:  I Sora; N Takahashi; M Funada; H Ujike; R S Revay; D M Donovan; L L Miner; G R Uhl
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

6.  Histone methyltransferases G9a and GLP form heteromeric complexes and are both crucial for methylation of euchromatin at H3-K9.

Authors:  Makoto Tachibana; Jun Ueda; Mikiko Fukuda; Naoki Takeda; Tsutomu Ohta; Hiroko Iwanari; Toshiko Sakihama; Tatsuhiko Kodama; Takao Hamakubo; Yoichi Shinkai
Journal:  Genes Dev       Date:  2005-03-17       Impact factor: 11.361

7.  Blocking mu opioid receptors in the spinal cord prevents the analgesic action by subsequent systemic opioids.

Authors:  Shao-Rui Chen; Hui-Lin Pan
Journal:  Brain Res       Date:  2006-02-24       Impact factor: 3.252

8.  Differential sensitivity of N- and P/Q-type Ca2+ channel currents to a mu opioid in isolectin B4-positive and -negative dorsal root ganglion neurons.

Authors:  Zi-Zhen Wu; Shao-Rui Chen; Hui-Lin Pan
Journal:  J Pharmacol Exp Ther       Date:  2004-07-27       Impact factor: 4.030

9.  Loss of TRPV1-expressing sensory neurons reduces spinal mu opioid receptors but paradoxically potentiates opioid analgesia.

Authors:  Shao-Rui Chen; Hui-Lin Pan
Journal:  J Neurophysiol       Date:  2006-02-08       Impact factor: 2.714

10.  G9a is essential for epigenetic silencing of K(+) channel genes in acute-to-chronic pain transition.

Authors:  Geoffroy Laumet; Judit Garriga; Shao-Rui Chen; Yuhao Zhang; De-Pei Li; Trevor M Smith; Yingchun Dong; Jaroslav Jelinek; Matteo Cesaroni; Jean-Pierre Issa; Hui-Lin Pan
Journal:  Nat Neurosci       Date:  2015-11-09       Impact factor: 24.884

View more
  26 in total

1.  μ-Opioid receptors in primary sensory neurons are essential for opioid analgesic effect on acute and inflammatory pain and opioid-induced hyperalgesia.

Authors:  Jie Sun; Shao-Rui Chen; Hong Chen; Hui-Lin Pan
Journal:  J Physiol       Date:  2019-01-16       Impact factor: 5.182

2.  Histone methyltransferase G9a diminishes expression of cannabinoid CB1 receptors in primary sensory neurons in neuropathic pain.

Authors:  Yi Luo; Jixiang Zhang; Lin Chen; Shao-Rui Chen; Hong Chen; Guangfen Zhang; Hui-Lin Pan
Journal:  J Biol Chem       Date:  2020-02-04       Impact factor: 5.157

3.  Transmission pathways and mediators as the basis for clinical pharmacology of pain.

Authors:  Daniel R Kirkpatrick; Dan M McEntire; Tyler A Smith; Nicholas P Dueck; Mitchell J Kerfeld; Zakary J Hambsch; Taylor J Nelson; Mark D Reisbig; Devendra K Agrawal
Journal:  Expert Rev Clin Pharmacol       Date:  2016-07-04       Impact factor: 5.045

4.  Contribution of the Suppressor of Variegation 3-9 Homolog 1 in Dorsal Root Ganglia and Spinal Cord Dorsal Horn to Nerve Injury-induced Nociceptive Hypersensitivity.

Authors:  Jun Zhang; Lingli Liang; Xuerong Miao; Shaogen Wu; Jing Cao; Bo Tao; Qingxiang Mao; Kai Mo; Ming Xiong; Brianna Marie Lutz; Alex Bekker; Yuan-Xiang Tao
Journal:  Anesthesiology       Date:  2016-10       Impact factor: 7.892

5.  The transcription factor C/EBPβ in the dorsal root ganglion contributes to peripheral nerve trauma-induced nociceptive hypersensitivity.

Authors:  Zhisong Li; Yuanyuan Mao; Lingli Liang; Shaogen Wu; Jingjing Yuan; Kai Mo; Weihua Cai; Qingxiang Mao; Jing Cao; Alex Bekker; Wei Zhang; Yuan-Xiang Tao
Journal:  Sci Signal       Date:  2017-07-11       Impact factor: 8.192

6.  [Role of ZHX2 in regulating dorsal root ganglion μ-opioid receptor expression in mice with peripheral nerve injuryinduced pain hypersensitivity].

Authors:  Hengwei Sheng; Kai Mo
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-08-30

7.  RE1-silencing transcription factor controls the acute-to-chronic neuropathic pain transition and Chrm2 receptor gene expression in primary sensory neurons.

Authors:  Jixiang Zhang; Shao-Rui Chen; Hong Chen; Hui-Lin Pan
Journal:  J Biol Chem       Date:  2018-10-16       Impact factor: 5.157

8.  BIX01294, a G9a inhibitor, alleviates nerve injury-induced pain hypersensitivities during both development and maintenance periods.

Authors:  Lingli Liang; Jian-Yuan Zhao; Ticehurst Kathryn; Alex Bekker; Yuan-Xiang Tao
Journal:  Transl Perioper Pain Med       Date:  2019-08-14

Review 9.  From Mechanism to Cure: Renewing the Goal to Eliminate the Disease of Pain.

Authors:  Theodore J Price; Michael S Gold
Journal:  Pain Med       Date:  2018-08-01       Impact factor: 3.750

10.  Mitogen-activated protein kinase signaling mediates opioid-induced presynaptic NMDA receptor activation and analgesic tolerance.

Authors:  Meichun Deng; Shao-Rui Chen; Hong Chen; Yi Luo; Yingchun Dong; Hui-Lin Pan
Journal:  J Neurochem       Date:  2018-12-10       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.